The changes to Medicaid rebates that are paring some drug companies' sales and earnings may also cut into already-ailing state budgets. The healthcare overhaul increases the minimum brand name drug discount to 23.1% from 15.1%, but also changes how the funds are split between the states and the feds, shifting a "significant portion" to the latter. A spokeswoman for Sen. Majority Leader Harry Reid says the states are benefiting from the $434 billion, 10-year increase in Medicaid spending that the redistributed rebates will help fund. But a Kaiser Health News
analysis finds that only Arizona, Massachusetts, and New Mexico would come out ahead with the new rebate policy.